These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 10471051)

  • 1. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
    Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer.
    Helmig S; Schneider J
    Expert Rev Mol Diagn; 2007 Sep; 7(5):555-68. PubMed ID: 17892364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
    Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
    Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
    Nelson HH; Christiani DC; Wiencke JK; Mark EJ; Wain JC; Kelsey KT
    Cancer Res; 1999 Sep; 59(18):4570-3. PubMed ID: 10493509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
    Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
    Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
    Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
    Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure.
    Husgafvel-Pursiainen K; Kannio A; Oksa P; Suitiala T; Koskinen H; Partanen R; Hemminki K; Smith S; Rosenstock-Leibu R; Brandt-Rauf PW
    Environ Mol Mutagen; 1997; 30(2):224-30. PubMed ID: 9329647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
    Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
    Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.
    Isik R; Metintas M; Gibbs AR; Metintas S; Jasani B; Oner U; Harmanci E; Demircan S; Işiksoy S
    Respir Med; 2001 Jul; 95(7):588-93. PubMed ID: 11453316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An enzyme immunoassay for auto-antibodies to keratin in normal human serum and in pleural fluids from patients with various malignant or non-malignant lung diseases.
    Lambré CR; Alaoui-Slimani N; Bignon J
    J Clin Lab Immunol; 1986 Aug; 20(4):171-6. PubMed ID: 2428981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
    Attanoos RL; Thomas DH; Gibbs AR
    Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
    Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
    N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
    Amati M; Tomasetti M; Mariotti L; Tarquini LM; Valentino M; Santarelli L
    Mutat Res; 2008; 655(1-2):52-8. PubMed ID: 18638565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.